Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC. METHODS: The open-label, phase 1, mult...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Hellmann, Matthew D, Rizvi, Naiyer A, Goldman, Jonathan W, Gettinger, Scott N, Borghaei, Hossein, Brahmer, Julie R, Ready, Neal E, Gerber, David E, Chow, Laura Q, Juergens, Rosalyn A, Shepherd, Frances A, Laurie, Scott A, Geese, William J, Agrawal, Shruti, Young, Tina C, Li, Xuemei, Antonia, Scott J
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5476941/
https://ncbi.nlm.nih.gov/pubmed/27932067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30624-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados